Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

NCT03145012 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: Ranitidine

Sponsor

Nova Scotia Health Authority

Collaborators

[object Object]